Exploring Therapeutic Potentials and Pathways of Psychedelics in Alzheimer’s Disease‐Related Dementia

Psychedelics such as DMT, LSD, and psilocybin, traditionally linked to recreational and spiritual use, are being investigated for therapeutic benefits in Alzheimer's disease-related dementia. These compounds act as serotonin agonists and enhance neural plasticity through serotonin and glutamate systems. They may modulate Alzheimer's-related signaling pathways, including the BDNF pathway, mTOR activation, and autophagy regulators. Controlled administration, depending on dosage, offers a potential novel intervention for dementia. The review highlights promising pathways but emphasizes the need for further studies to establish long-term safety, efficacy, and optimal treatment protocols.

Study at a glance

Abstract

Abstract Background Traditionally associated with recreational and spiritual uses, psychedelics have gained attention in psychotherapy for their therapeutic potential. Functioning as potent 5‐hydroxytryptamine (5HT) agonists, these compounds have demonstrated the ability to enhance neural plasticity by activating serotoninergic and glutamatergic systems. Despite these recognized effects, their role in treating neurodegenerative disorders, particularly dementia, remains relatively unexplored. Method Recent studies have unveiled modulatory and beneficial impacts of psychedelics, including N, N‐dimethyltryptamine (DMT), Lysergic acid diethylamide (LSD), and Psilocybin, in Alzheimer’s disease (AD)‐related dementia. These compounds target neurotransmitter imbalances and molecularly modulate AD‐related signaling pathways, such as the Brain‐derived neurotrophic factor (BDNF) pathway, mTOR activation, and other autophagy regulators. Result The controlled administration of psychedelics, contingent on dosage, presents a novel therapeutic intervention for AD‐related dementia, warranting exploration for drug development. This review critically examines existing literature on the therapeutic potential and pathways of psychedelics for AD‐related dementia. Conclusion While promising, further studies are imperative to establish long‐term safety, efficacy, and optimal treatment protocols. Integrating psychedelics into the treatment paradigm may offer a transformative approach to address the unmet needs of individuals with AD‐related dementia and their caregivers.